Danaher's diagnostics platform generates approximately $8 billion in IVD revenues in 2025, comprising Beckman Coulter Diagnostics in clinical chemistry and immunoassay, Cepheid in molecular diagnostics, Radiometer in critical care and blood gas testing, and Leica Biosystems in anatomic pathology and digital pathology. Cepheid's GeneXpert platform — with over 50,000 installed instruments across more than 180 countries — is the global leader in near-patient molecular testing for tuberculosis, HIV, hepatitis, and infectious disease syndromic panels. Beckman Coulter's DxC series competes directly with Roche cobas, Abbott Alinity, and Siemens Atellica for core laboratory consolidation. Leica Biosystems positions Danaher at the forefront of computational pathology.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — GeneXpert Expansion, Core Lab Consolidation, and Digital Pathology Through 2030
• Financial Performance — Revenue, Revenue by Business Unit, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — GeneXpert, DxC, Radiometer AQT, and Leica Digital Pathology
• Latest Products and Services — Platform Launches, Menu Expansions, and Innovation Pipeline
• M&A — Acquisitions, Divestitures, and Partnerships 2023-2025
• Marketing Tactics — Multi-Brand Strategy, Reagent Rental, and Channel Management
• Organization and Management — Leadership, Structure, and Workforce
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Danaher Diagnostics — Key Financial Metrics Summary 2023-2025
Table 2. Danaher Diagnostics — Revenue by Segment 2023-2025
Table 3. Danaher Diagnostics — Revenue by Geography 2023-2025
Table 4. Danaher Diagnostics — R&D Investment 2023-2025
Table 5. Danaher Diagnostics — SWOT Analysis
Table 6. Danaher Diagnostics — Core Technology Capabilities and Key Platforms
Table 7. Danaher Diagnostics — Key Analyzers and Reagent Portfolio
Table 8. Danaher Diagnostics — M&A Activity Summary 2023-2025
Table 9. Danaher Diagnostics — Key Management and Leadership
Table 10. Danaher Diagnostics — Strategic Priorities 2025-2030
